Literature DB >> 12829595

Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia.

Xiaoyan Jiang1, Matthew Stuible, Yves Chalandon, Andra Li, Wing Yiu Chan, Wolfgang Eisterer, Gerald Krystal, Allen Eaves, Connie Eaves.   

Abstract

Previous studies suggested that the SH2-containing inositol-5-phosphatase (SHIP) may play a tumor suppressor-like function in BCR-ABL-mediated leukemogenesis. To investigate this possibility, we first developed a new assay for quantitating transplantable multilineage leukemia-initiating cells (L-ICs) in hematopoietic stem cell (HSC)-enriched mouse bone marrow (BM) cells transduced with a BCR-ABL-GFP (green fluorescent protein) retrovirus. The frequency of L-ICs (1 of 430 Sca-1+lin- cells) was 7-fold lower than the frequency of HSCs in the Sca-1+lin- subset transduced with a control virus (1 of 65 cells). Forced BCRABL expression was also accompanied by a loss of regular HSC activity consistent with the acquisition of an increased probability of differentiation. Interestingly, the frequency and in vivo behavior of wild-type (+/+) and SHIP-/- L-ICs were indistinguishable, and in vitro, Sca-1+lin- BCR-ABL-transduced SHIP-/- cells showed a modestly reduced factor independence. Comparison of different populations of cells from patients with chronic myeloid leukemia (CML) in chronic phase and normal human BM showed that the reduced expression of full-length SHIP proteins seen in the more mature (CD34-lin+) leukemic cells is not mirrored in the more primitive (CD34+lin-) leukemic cells. Thus, SHIP expression appears to be differently altered in the early and late stages of differentiation of BCR-ABL-transformed cells, underscoring the importance of the cellular context in which its mechanistic effects are analyzed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829595     DOI: 10.1182/blood-2003-05-1550

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Authors:  Yi-Fen Lu; L Cristina Gavrilescu; Monica Betancur; Katherine Lazarides; Hans Klingemann; Richard A Van Etten
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Grb10 is involved in BCR-ABL-positive leukemia in mice.

Authors:  A L Illert; C Albers; S Kreutmair; H Leischner; C Peschel; C Miething; J Duyster
Journal:  Leukemia       Date:  2014-09-24       Impact factor: 11.528

3.  Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1.

Authors:  Fengyin Li; Bing He; Xiaoke Ma; Shuyang Yu; Rupali R Bhave; Steven R Lentz; Kai Tan; Monica L Guzman; Chen Zhao; Hai-Hui Xue
Journal:  Cell Stem Cell       Date:  2017-08-30       Impact factor: 24.633

4.  Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Authors:  Xianping Shi; Xin Chen; Xiaofen Li; Xiaoying Lan; Chong Zhao; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Wenbin Song; Ping Zhou; Shunqing Wang; Li Xu; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Clin Cancer Res       Date:  2013-12-12       Impact factor: 12.531

5.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

6.  Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.

Authors:  Laura S Haneline; Hilary White; Feng-Chun Yang; Shi Chen; Christie Orschell; Reuben Kapur; David A Ingram
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

7.  Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Authors:  Shengqing Gu; Wayne W Chan; Golam Mohi; Joel Rosenbaum; Azin Sayad; Zhibin Lu; Carl Virtanen; Shaoguang Li; Benjamin G Neel; Richard A Van Etten
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

8.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.